Efficacy Of A Combination Of Desloratadine And Mometasone Furoate Nasal Spray In Subjects With Cough Associated With Persistent Allergic Rhinitis

Abstract

RATIONALE: Persistent Allergic Rhinitis (PAR) is the most common form of allergic rhinitis in Réunion Island (a tropical country). Cough is commonly associated with PAR. Allergic inflammation might contribute to cough by producing post nasal drip and by increasing pharyngeal irritability. This study assessed a combination of 5 mg of Desloratadine (DL) and 200 mg of Mometasone Furoate Nasal Spray (MFNS) vs DL 5 mg monotherapy in the treatment of cough associated with PAR.METHODS: The clinical study was performed in our Allergy Outpatient Clinic on patients (mean age 30.4 ± 10.5 years) with a > 1 year history of PAR symptoms, positive skin test to indoor allergens, moderate nasal symptoms and moderate cough. Patients were treated for 30 days with DL 5 mg/MFNS 200 mg/day (n = 146) or DL 5 mg qd (n = 144). Patients recorded cough and nasal symptoms using a 4 point scale (where 0 = no symptoms and 3 = severe symptoms).RESULTS: Total nasal symptoms improved significantly with DL 5 mg/MFNS 200 mg treatment. Overall (cough + total nasal)symptom scores also improved significantly compared with DL at endpoint (P < 0.05). Treatments were well tolerated, with no significant differences in the incidence of adverse events.CONCLUSIONS: The association of DL/MFNS is a valuable treatment of Persistent Allergic Rhinitis due to indoor allergens. This combination showed an important effect on cough with PAR, that was not alleviated by an antihistamine alone. RATIONALE: Persistent Allergic Rhinitis (PAR) is the most common form of allergic rhinitis in Réunion Island (a tropical country). Cough is commonly associated with PAR. Allergic inflammation might contribute to cough by producing post nasal drip and by increasing pharyngeal irritability. This study assessed a combination of 5 mg of Desloratadine (DL) and 200 mg of Mometasone Furoate Nasal Spray (MFNS) vs DL 5 mg monotherapy in the treatment of cough associated with PAR. METHODS: The clinical study was performed in our Allergy Outpatient Clinic on patients (mean age 30.4 ± 10.5 years) with a > 1 year history of PAR symptoms, positive skin test to indoor allergens, moderate nasal symptoms and moderate cough. Patients were treated for 30 days with DL 5 mg/MFNS 200 mg/day (n = 146) or DL 5 mg qd (n = 144). Patients recorded cough and nasal symptoms using a 4 point scale (where 0 = no symptoms and 3 = severe symptoms). RESULTS: Total nasal symptoms improved significantly with DL 5 mg/MFNS 200 mg treatment. Overall (cough + total nasal)symptom scores also improved significantly compared with DL at endpoint (P < 0.05). Treatments were well tolerated, with no significant differences in the incidence of adverse events. CONCLUSIONS: The association of DL/MFNS is a valuable treatment of Persistent Allergic Rhinitis due to indoor allergens. This combination showed an important effect on cough with PAR, that was not alleviated by an antihistamine alone.